Flu vaccine works in HIV-positive individuals

Michael Carter
Published: 26 May 2005

Influenza vaccine is effective in HIV-positive patients, according to the results of a large prospective Japanese study published in the June 1st edition of the Journal of Acquired Immune Deficiency Syndromes. The investigators also found that CD4 cell count predicted the effectiveness of influenza vaccination in patients who did not have antibodies to influenza before vaccination.

Vaccination against influenza is recommended for HIV-positive individuals. “Influenza virus infection may be more prolonged in individuals with immune deficiency and can cause a transient increase in HIV-q viral load that might become relevant to the clinical course of HIV-1 infection”, write the investigators.

There have, however, been few studies looking at the protective effect of influenza vaccine in HIV-positive patients. These studies did not consider the effect of HIV viral load or the impact of HAART on immune restoration or on the efficacy of influenza vaccination.

Japanese investigators therefore wished to determine the clinical efficacy of influenza vaccination and to correlate it with immune response to the vaccine determined by increased antibody levels and anti-influenza specific CD4 T -cells.

Between November and December 2002, patients attending a large HIV outpatient clinic were offered influenza vaccination. The investigators restricted their analysis to a random selection of 262 individuals who accepted the vaccination and 66 patients who declined it.

Blood samples were obtained at the time of vaccination and then after eight and/or 16 weeks to determine immunological response to the vaccine, CD4 cell count and HIV viral load.

A total of 30 cases of influenza occurred in the study population, 16 cases in patients who received the vaccine (6%) and 14 cases in individuals who declined vaccination (21%). This difference was statistically significant (p < 0.001).

CD4 cell count was a factor in the risk of developing influenza. Amongst patients with a CD4 cell count above 200 cells/mm3 the incidence of influenza was 6% in vaccinated patients and 21% in unvaccinated patients. Once again, this difference was statistically significant (p < 0.001). The size of the study population meant that it was not possible to undertake a statistical analysis of the risk of developing influenza for vaccinated and unvaccinated patients with a CD4 cell count below 200 cells/mm3.

The investigators then looked at the incidence of influenza in patients according to the use of HAART. They found that 6% of vaccinated individuals taking HAART developed influenza compared to 21% of unvaccinated patients taking HAART (p < 0.002). The incidence of influenza was remarkably similar for patients not taking antiretroviral therapy. Once again, 6% of vaccinated individuals became ill with influenza compared to 22% of unvaccinated patients (p < 0.05).

In multivariate analysis, the investigators identified CD4 cell count (p < 0.05) and vaccination (p < 0.001) but not HIV viral load as being independent predictors of the risk of influenza.

Influenza antibody titers were tested at weeks eight and/or 16 after vaccination. In patients who did not have antibodies to influenza at baseline, antibody response after vaccination was significantly affected by whether an individual had a CD4 cell count above or below 200 cells/mm3 (p < 0.05). Antibody response was not influenced, however, by HIV viral load.

Amongst patients who had influenza antibodies at baseline, the response to the vaccination was not affected by whether a patient had a CD4 cell count above or below 200 cells/mm3.

The investigators then looked at influenza specific CD4 T-cell responses. They found that this response was affected by HIV viral load (p < 0.005), but not by CD4 cell count. In addition they found “specific CD4 T-cell responses were significantly increased by vaccination in HAART-treated patients (p = 0.001), because HIV viral load was decreased by HAART.”

The investigators conclude “our prospective study in a large population demonstrated that influenza vaccine provides protection of HIV-1 infected patients…annual vaccination of HIV-1 infected patients is thus recommended.”

Reference

Yamanaka H et al. Efficacy and immunologic response to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 39: 167 - 173, 2005.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.